中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 1
Jan.  2024
Turn off MathJax
Article Contents

Research advances in hepatic sinusoidal obstruction syndrome

DOI: 10.12449/JCH240104
More Information
  • Corresponding author: ZHANG Ming, mg0923@163.com (ORCID: 0009-0009-7742-3128)
  • Received Date: 2023-12-11
  • Accepted Date: 2023-12-20
  • Published Date: 2024-01-23
  • Hepatic sinusoidal obstruction syndrome (HSOS), also known as hepatic veno-occlusive disease, is hepatic vascular disease of hepatic sinusoidal obstruction and hepatic venular occlusion and fibrosis due to various causes. This article systematically elaborates on the research advances in HSOS from the aspects of understanding and naming, etiology and pathogenesis, clinical manifestation, diagnosis and differential diagnosis, prevention, and treatment. HSOS can occur in patients receiving bone marrow hematopoietic stem cell transplantation, radiotherapy/chemotherapy, and medication containing pyrrolidine alkaloids, and the common clinical manifestations of HSOS include abdominal distension, distending pain in the liver area, ascites, jaundice, and hepatomegaly. The diagnostic criteria for HSOS vary with etiology, and it needs to be differentiated from other diseases such as drug-induced liver diseases and hepatic venous outflow tract obstruction. Defibrotide and low-molecular-weight heparin have a therapeutic effect on HSOS associated with hematopoietic stem cells and pyrrolidine alkaloids, respectively, and there are currently no effective drugs for HSOS caused by oxaliplatin chemotherapy.

     

  • loading
  • [1]
    VALLA DC, CAZALS-HATEM D. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2016, 40( 4): 378- 385. DOI: 10.1016/j.clinre.2016.01.006.
    [2]
    FAN CQ, CRAWFORD JM. Sinusoidal obstruction syndrome(hepatic veno-occlusive disease)[J]. J Clin Exp Hepatol, 2014, 4( 4): 332- 346. DOI: 10.1016/j.jceh.2014.10.002.
    [3]
    Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome(2017, Nanjing)[J]. J Clin Hepatol, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.

    中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
    [4]
    ZHUGE YZ, LIU YL, XIE WF, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol, 2019, 34( 4): 634- 642. DOI: 10.1111/jgh.14612.
    [5]
    BRAS G, JELLIFFE DB, STUART KL. Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica[J]. AMA Arch Pathol, 1954, 57( 4): 285- 300.
    [6]
    RUBBIA-BRANDT L, AUDARD V, SARTORETTI P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer[J]. Ann Oncol, 2004, 15( 3): 460- 466. DOI: 10.1093/annonc/mdh095.
    [7]
    ZHU C, REN XH, LIU D, et al. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome[J]. Toxicology, 2021, 460: 152882. DOI: 10.1016/j.tox.2021.152882.
    [8]
    CORBACIOGLU S, GRUPP SA, RICHARDSON PG, et al. Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: A never-ending story and no easy answer[J]. Bone Marrow Transplant, 2023, 58( 8): 839- 841. DOI: 10.1038/s41409-023-02007-2.
    [9]
    de LÉDINGHEN V, VILLATE A, ROBIN M, et al. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2020, 44( 4): 480- 485. DOI: 10.1016/j.clinre.2020.03.019.
    [10]
    MA YX, FENG YL, WU YY, et al. Toxic pyrrolizidine alkaloids in Chinese herbal medicine: Control status and advances in analytical method[J]. Chin Tradit Herb Drugs, 2021, 52( 24): 7645- 7657. DOI: 10.7501/j.issn.0253-2670.2021.24.028.

    马跃新, 冯有龙, 吴嫣艳, 等. 中草药中毒性吡咯里西啶类生物碱分析方法研究进展及控制现状[J]. 中草药, 2021, 52( 24): 7645- 7657. DOI: 10.7501/j.issn.0253-2670.2021.24.028.
    [11]
    ÖZKAN HA, ÖZKAN SG. Hepatic veno-occlusive disease(sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation in adult patients: Diagnosis, incidence, prophylaxis, and treatment[J]. Transfus Apher Sci, 2022, 61( 1): 103372. DOI: 10.1016/j.transci.2022.103372.
    [12]
    MOHTY M, MALARD F, ABECASSIS M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 2016, 51( 7): 906- 912. DOI: 10.1038/bmt.2016.130.
    [13]
    WAESPE N, STREBEL S, JURKOVIC MLAKAR S, et al. Genetic predictors for sinusoidal obstruction syndrome-a systematic review[J]. J Pers Med, 2021, 11( 5): 347. DOI: 10.3390/jpm11050347.
    [14]
    KUMAR A, PALEK R, LISKA V. A critical analysis of experimental animal models of sinusoidal obstruction syndrome[J]. J Clin Exp Hepatol, 2019, 9( 3): 345- 353. DOI: 10.1016/j.jceh.2018.07.002.
    [15]
    TODA R, SEO S, UEMOTO Y, et al. Clinically relevant model of oxaliplatin-induced sinusoidal obstruction syndrome[J]. Hepatol Res, 2023, 53( 2): 145- 159. DOI: 10.1111/hepr.13842.
    [16]
    CALISTRI L, RASTRELLI V, NARDI C, et al. Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis[J]. World J Gastroenterol, 2021, 27( 46): 7866- 7893. DOI: 10.3748/wjg.v27.i46.7866.
    [17]
    LIU L, ZHANG W, ZHUGE YZ. Review on diagnostic criteria of hepatic sinusoidal obstruction syndrome[J]. Chin J Hepatol, 2020, 28( 12): 1064- 1068. DOI: 10.3760/cma.j.cn501113-20190415-00124.

    刘璐, 张玮, 诸葛宇征. 肝窦阻塞综合征诊断标准综述[J]. 中华肝脏病杂志, 2020, 28( 12): 1064- 1068. DOI: 10.3760/cma.j.cn501113-20190415-00124.
    [18]
    CHAO N. How I treat sinusoidal obstruction syndrome[J]. Blood, 2014, 123( 26): 4023- 4026. DOI: 10.1182/blood-2014-03-551630.
    [19]
    CORBACIOGLU S. Sinusoidal obstruction syndrome(SOS) and defibrotide: We are not there yet[J]. Transplant Cell Ther, 2023, 29( 5): 287- 288. DOI: 10.1016/j.jtct.2023.03.032.
    [20]
    COLECCHIA A, RAVAIOLI F, SESSA M, et al. Liver stiffness measurement allows early diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome in adult patients who undergo hematopoietic stem cell transplantation: Results from a monocentric prospective study[J]. Biol Blood Marrow Transplant, 2019, 25( 5): 995- 1003. DOI: 10.1016/j.bbmt.2019.01.019.
    [21]
    ZHANG W, LIU L, ZHANG M, et al. Validation of the Nanjing criteria for diagnosing pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome[J]. J Clin Transl Hepatol, 2021, 9( 3): 345- 352. DOI: 10.14218/JCTH.2020.00124.
    [22]
    CUTLER C, KIM HT, AYANIAN S, et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury[J]. Biol Blood Marrow Transplant, 2010, 16( 8): 1180- 1185. DOI: 10.1016/j.bbmt.2010.02.016.
    [23]
    TONG YR, ZHANG M, QI ZX, et al. Hepatic venous occlusion type of budd-chiari syndrome versus pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome: A multi-center retrospective study[J]. J Pers Med, 2023, 13( 4): 603. DOI: 10.3390/jpm13040603.
    [24]
    PENG C, ZHANG X, ZHANG F, et al. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study[J]. Eur J Gastroenterol Hepatol, 2020, 32( 9): 1168- 1178. DOI: 10.1097/MEG.0000000000001630.
    [25]
    WU F, YU JA, GAN HY, et al. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. Sci Rep, 2021, 11: 21743. DOI: 10.1038/s41598-021-01201-w.
    [26]
    WANG X, ZHANG W, ZHANG M, et al. Development of a Drum Tower Severity Scoring(DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. Hepatol Int, 2022, 16( 3): 669- 679. DOI: 10.1007/s12072-021-10293-5.
    [27]
    XIAO J, TU J, ZHANG H, et al. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt[J]. Hepatol Int, 2021, 15( 3): 720- 729. DOI: 10.1007/s12072-020-10126-x.
    [28]
    RUUTU T, JUVONEN E, REMBERGER M, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: Long-term follow-up of a randomized study[J]. Biol Blood Marrow Transplant, 2014, 20( 1): 135- 138. DOI: 10.1016/j.bbmt.2013.10.014.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (752) PDF downloads(191) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return